Resumen de BRAF mutations among patients from the Northeast of México with malignant melanoma

Óscar Raúl Fajardo Ramírez, Julio César Salas Alanis, Eduardo Guzmán Huerta, Ubaldo Martínez, Álvaro Barbosa, Sean-Patrick Scott, José A. Hernández Hernández, Luis Mario Villela Martínez

• According to the American Cancer Society, metastatic melanoma represents only 5% of all dermatology malignancies in the skin, but it is responsible for 80% of all deaths. Due to a delay in diagnosis, it is estimated that only 14% of patients survive 5 years after diagnosis.2 BRAF mutation has been reported in multiples types of cancer but there is currently no information on the prevalence of the BRAF mutation among Latin-Americans, especially in Mexican population. The most frequent mutation in this oncogen (BRAF V600) represents the 90% of cases, therefore the objective of the study is to determine the prevalence of the BRAF mutation among a sample of patients with melanoma from the Northeast of México and correlate it to clinical characteristics.